Singapore-based Gero raises USD 2.2 million to develop anti-ageing drug

Singapore: Singapore-based Gero an AI platform that develops new drugs to combat aging and other disorders, today announced that it has raised US$2.2 million in a series A funding round, bringing its total capital raised to over US$7.5 million.

The round was led by machine learning-focused VC firm Bulba Ventures, along with existing investors and serial entrepreneurs in the fields of pharmaceuticals, IT, and AI. Yury Melnichek, co-founder of Bulba Ventures, has joined Gero’s board of directors.

The startup will use the new funds to further develop its AI platform for analyzing clinical and genetic data to identify treatments for chronic aging-related diseases, mental disorders, and other diseases.